Essential Partners’s Foghorn Therapeutics FHTX Stock Holding History

Essential Partners’s Portfolio FHTX Stock Details FHTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$121	Sell	34 -1	-3%	-$5	﹤0.01%	2676
2026 Q2	$171	Sell	35 -77	-69%	-$342	﹤0.01%	2667
2026 Q1	$535	Buy	+112	New	+$615	﹤0.01%	2418
2025 Q4	–	Sell	-5	Closed	-$24	–	2819
2025 Q3	$24	Hold	5	–	–	﹤0.01%	2624
2025 Q2	$24	Buy	+5	New	+$21	﹤0.01%	2212

Other funds holding FHTX

TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

TWD

True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

Essential Partners's FHTX Position: Q3 2026 in Review

Essential Partners reduced its Foghorn Therapeutics (FHTX) stake by 2.9% in Q3 2026, selling an estimated $5 and leaving 34 shares worth $121. The position accounts for ﹤0.01% of the portfolio, ranked #2676.

Essential Partners first reported a position in FHTX in Q2 2025 and has held it in 5 quarters since. The position peaked at $535 in Q1 2026. 5 funds tracked by Wall St. Rank hold FHTX as of Q3 2026.

Essential Partners held 34 shares of Foghorn Therapeutics worth $121 as of Q3 2026.
Essential Partners sold 1 Foghorn Therapeutics share in Q3 2026, an estimated $5.
Foghorn Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q3 2026, its #2676 holding.
Essential Partners first reported a position in Foghorn Therapeutics in Q2 2025 and has held it in 5 quarters since.
Essential Partners's Foghorn Therapeutics position peaked at $535 in Q1 2026.
5 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.